Nanjing-based MeiRui focuses on the urology therapeutic area – the company’s drugs include naftopidil and finasteride, both used in the setting of benign prostatic hyperplasia, as well as tolterodine, for incontinence. GSK markets dutasteride (Avodart) outside of China for BPH.
GlaxoSmithKline (GSK) to purchase China specialty pharmaceutical player Nanjing MeiRui Pharma upwards of USD 100 million